Over the past decade, average out-of-pocket costs for obese individuals with employer coverage have increased by 37 percent, reaching $1,487 in 2021.[33] In comparison, individuals without obesity saw a 25 percent increase, averaging $698 per year
If you're researching medical weight loss options, you've likely come across Wegovy and Ozempic, two medications containing semaglutide
These assets enable fast, consistent, and reproducible screening of both single and dual agonist compounds, accelerating the discovery of next-generation therapeutics in this pathway
This is especially a concern in individuals with pre-existing kidney disease or those taking other medications that affect renal function, such as NSAIDs or diuretics